Dennis Langer - 14 Oct 2025 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Reporting relationship: Director
Issuer ticker: QNRX
Reported as of: 14 Oct 2025
Net transaction value: +$128,640
SEC form: 4
Accepted by SEC: 15 Oct 2025, 17:15:20 UTC
Prior SEC filing: 25 Aug 2025
Next SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Dennis Langer

Key filing fact

Dennis Langer filed Form 4 for Quoin Pharmaceuticals, Ltd. (QNRX) on 15 Oct 2025.

Key facts

This page summarizes Dennis Langer's Form 4 filing for Quoin Pharmaceuticals, Ltd. (QNRX).
5 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 15 Oct 2025, 17:15.

Change

Previous filing in this sequence was filed on 25 Aug 2025.
Current net transaction value: +$128,640.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001274225 Primary reporting owner

LANGER DENNIS

Relationship: Director
Address: C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN
Signature: /s/ Dennis Langer
Signature date: 15 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QNRX transaction

ADSs

Purchase

Transaction value: $128,640
Shares: +15,152
Change %: +1515200%
Price: $8.49
Shares after: 15,153
Date: 14 Oct 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNRX transaction Derivative

Series H Warrants (Right to Buy)

Purchase

Transaction value
Shares: +15,152
Change %
Price
Shares after: 15,152
Date: 14 Oct 2025
Ownership: Direct
Underlying class: ADS
Underlying amount: 15,152
Exercise price: $9.08
Footnotes: F1, F2, F3, F4

QNRX transaction Derivative

Series I Warrants (Right to Buy)

Purchase

Transaction value
Shares: +15,152
Change %
Price
Shares after: 15,152
Date: 14 Oct 2025
Ownership: Direct
Underlying class: ADS
Underlying amount: 15,152
Exercise price: $10.31
Footnotes: F1, F2, F3, F5

QNRX transaction Derivative

Series J Warrants (Right to Buy)

Purchase

Transaction value
Shares: +15,152
Change %
Price
Shares after: 15,152
Date: 14 Oct 2025
Ownership: Direct
Underlying class: ADS
Underlying amount: 15,152
Exercise price: $12.38
Footnotes: F1, F2, F3, F6

QNRX transaction Derivative

Series K Warrants (Right to Buy)

Purchase

Transaction value
Shares: +15,152
Change %
Price
Shares after: 15,152
Date: 14 Oct 2025
Ownership: Direct
Underlying class: ADS
Underlying amount: 15,152
Exercise price: $12.38
Footnotes: F1, F2, F3, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Footnote F2

Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

Footnote F3

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

Footnote F4

The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.

Footnote F5

The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.

Footnote F6

The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.

Footnote F7

The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).